215 related articles for article (PubMed ID: 33457101)
1. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Qin W; Zou J; Huang Y; Liu C; Kang Y; Han H; Tang Y; Li L; Liu B; Zhao W; Yuan X
Oncoimmunology; 2020 Sep; 9(1):1824631. PubMed ID: 33457101
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
4. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
Ebrahimpour A; Ahir M; Wang M; Jegga AG; Bonnen MD; Eissa NT; Montesi SB; Raghu G; Ghebre YT
Sci Rep; 2022 Nov; 12(1):20668. PubMed ID: 36450789
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Tan J; Xue Q; Hu X; Yang J
J Transl Med; 2024 Jan; 22(1):95. PubMed ID: 38263193
[TBL] [Abstract][Full Text] [Related]
8. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.
Karampitsakos T; Galaris A; Chrysikos S; Papaioannou O; Vamvakaris I; Barbayianni I; Kanellopoulou P; Grammenoudi S; Anagnostopoulos N; Stratakos G; Katsaras M; Sampsonas F; Dimakou K; Manali ED; Papiris S; Tourki B; Juan-Guardela BM; Bakakos P; Bouros D; Herazo-Maya JD; Aidinis V; Tzouvelekis A
Respir Res; 2023 Nov; 24(1):279. PubMed ID: 37964265
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
Potts J; Yogaratnam D
Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis.
Rasooli R; Pourgholamhosein F; Kamali Y; Nabipour F; Mandegary A
Inflammation; 2018 Feb; 41(1):134-142. PubMed ID: 28921394
[TBL] [Abstract][Full Text] [Related]
13. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
14. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
[TBL] [Abstract][Full Text] [Related]
16. Role of transient receptor potential vanilloid 4 in therapeutic antifibrotic effects of pirfenidone.
Kuronuma K; Otsuka M; Wakabayashi M; Yoshioka T; Kobayashi T; Kameda M; Morioka Y; Chiba H; Takahashi H
Am J Physiol Lung Cell Mol Physiol; 2022 Aug; 323(2):L193-L205. PubMed ID: 35787697
[TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A
Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685
[TBL] [Abstract][Full Text] [Related]
18. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
20. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
